论文部分内容阅读
目的:研究促红细胞生成素对慢性心衰患者血栓风险的影响。方法:43例慢性心力衰竭合并轻度贫血的患者,随机分为2组:促红细胞生成素(EPO)组(22例)及对照组(21例)。EPO组患者给予多糖铁复合物胶囊150mg,2次/d加EPO每周10000～15000U。对照组患者给予多糖铁复合物胶囊150mg,2次/d。血红蛋白目标值为135g/L,疗程为3个月。治疗3个月后,用ELISA法测定4种血栓分子标志物浓度,包括凝血酶-抗凝血酶Ⅲ复合物(TAT)、凝血酶原片段1+2(F1+2)、D-二聚体(D-D)、纤溶酶-抗纤溶酶复合物(PAP)。结果:EPO组治疗前后以及EPO组和对照组治疗后,4种血栓分子标志物的比较差异均无统计学意义(P均>0.05)。结论:慢性心力衰竭患者接受EPO每周10000～15000U治疗未明显增加潜在血栓风险。
Objective: To investigate the effect of erythropoietin on the risk of thrombosis in patients with chronic heart failure. Methods: Forty-three patients with chronic heart failure and mild anemia were randomly divided into two groups: EPO group (n = 22) and control group (n = 21). EPO group patients given polysaccharide iron compound capsules 150mg, 2 times / d plus EPO 10000 ~ 15000U per week. Control group patients given polysaccharide iron compound capsules 150mg, 2 times / d. Hemoglobin target value of 135g / L, treatment for 3 months. Three months after treatment, the concentrations of the four thrombi molecular markers including thrombin-antithrombin III complex (TAT), prothrombin fragment 1 + 2 (F1 + 2), D-dimer Body (DD), plasmin - antiplasmin complex (PAP). Results: There was no significant difference in the four thrombus molecular markers before and after EPO treatment and after EPO treatment and control group (all P> 0.05). CONCLUSIONS: Treatment of EPO by 10,000 to 15,000 U per week in patients with chronic heart failure did not significantly increase the potential risk of thrombosis.